Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response

Table 1 Descriptive characteristics of study participants

	Mean ± standard deviation or N (%)
N (%)	595 (100)
Randomized to hydrochlorothiazide, N (%)	302 (51)
Age, years	49.3 ± 9.1
Male, N (%)	280 (47)
Black, N (%)	245 (41)
BMI, kg·m^-2	30.6 ± 5.6
Hypertension duration, years	7.1 ± 7.2
Antihypertensive medication, N (%)	492 (91)
Current smoker, N (%)	69 (13)
Glucose, mg·dL^-1	94.8 ± 10.5
Creatinine, mg·dL^-1	0.9 ± 0.2
Serum ALT, U·L^-1	29.1 ± 15.9
Plasma renin activity, ng·mL^-1·hr^-1	1.0 ± 1.2
Resting heart rate, beat·min^-1	71.0 ± 10.2
Screening office systolic BP, mmHg	137.9 ± 13.8
Screening office diastolic BP, mmHg	89.5 ± 8.8
Pretreatment systolic blood pressure, mmHg	151.5 ± 13.8
Pretreatment diastolic blood pressure, mmHg	98.2 ± 6.3

BMI, body mass index; ALT, alanine aminotransferase; BP, mmHg. Characteristics were measured at the screening visit except pretreatment systolic and diastolic BP and plasma renin activity were measured at the end of the drug-free washout period prior to initiating atenolol or hydrochlorothiazide therapy.

ISSN: 1479-5876